Adjuvant Strategies for Resectable Pancreatic Cancer: Have We Made Progress?

  • Suzanne Russo Department of Radiation Oncology, Mitchell Cancer Institute, University of South Alabama. Mobile, AL, USA
  • Anshu K Jain Department of Radiation Oncology, Columbia University Medical Center. New York, NY, USA
  • Muhammad Wasif Saif Division of Hematology and Oncology, Department of Medicine, Columbia University Medical Center. New York, NY, USA
Keywords: Chemoradiotherapy, Adjuvant, Radiation, Pancreatic Neoplasms


Substantial controversy remains regarding the optimal adjuvant treatment for patients with resectable pancreatic adenocarcinoma. Despite improvements in radiation techniques, systemic therapies, and incorporation of targeted agents, the 5-year survival rates for early stage patients remains less than 25% and the optimal adjuvant treatment approach remains unclear. Here we summarize the data presented at the 2012 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium regarding controversial issues surrounding the role, timing, and selection of patients for adjuvant chemoradiation strategies following curative resection for pancreatic adenocarcinoma. (Abstracts #301, #333, and #206).


Download data is not yet available.

Author Biography

Suzanne Russo, Department of Radiation Oncology, Mitchell Cancer Institute, University of South Alabama. Mobile, AL, USA

Philip Rubin Professor of Interdisciplinary Oncology

Department of Radiation Oncology


American Cancer Society Cancer Facts and Figures 2011. (, Atlanta, 2011)

Howlader N, Noone A, Krapch, M et al. SEER Cancer Statistics Review, 1975-2008. (Ed) (National Cancer Institute, Bethesda, MD, 2010)

Chang DK, Johns AL, Merrett ND et al. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol, 2009. 27(17): 2855-2862. [PMID 19398572]

Farnell MB, Pearson RK, Sarr MG et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005. 138(4): 618-628; discussion 628-630 [PMID 16269290]

Tepper J, Nardi G, Sutt H. Carcinoma of the pancreas: review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy. Cancer 1976. 37(3): 1519-1524 [PMID 1260670]

Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 2006. 10(4): 511-518 [PMID 16627216]

Hsu CC, Herman JM, Corsini MM et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol 2010. 17(4): 981-990 [PMID 20087786]

Van Laethem JL, Hammel P, Mornex F et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol 2010. 28(29): 4450-4456 [PMID 20837948]

Abrams RA. Gemcitabine hydrochloride with or without erlotinib hydrochloride followed by the same chemotherapy regimen with or without radiation therapy and capecitabine or fluorouracil in treating patients with pancreatic cancer that has been removed by surgery. In: National Institutes of Health,; NCT Number: NCT01013649 NCT01013649?term=rtog+0848&rank=1

Childs SK, Mamon HJ, Yon-Li Wo J, Blaszkowsky LS, Fernandez-del Castillo C, Swanson R, Wolpin BM, Kwak EL, Allen JN, Zhu AX, Clark JW, Wadlow RC, Ryan DP, Hong TS. Immediate versus delayed adjuvant chemoradiation for resected pancreatic cancer: An analysis of local control and survival. J ClinOncol 2012. 30: (suppl 4; abstr 301).

Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987. 59(12), 2006-2010 [PMID 3567862]

Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Sur 1985. 120(8), 899-903 [PMID 4015380]

Yang X, Sing-Ying Wu C, Hwang JJ, Weinberg B, Pishvaian MJ, He AR, Marshall J. Maintenance therapy with capecitabine in patients with resected pancreatic adenocarcinoma after adjuvant therapy. J ClinOncol2012. 30: (suppl 4; abstr 333).

Fisher SB, Patel SH, Bagci P, Kooby DA, El-Rayes BF, Staley CA, VolkanAdsay N, Maithel SK. An analysis of ERCC1, hENT1, RRM1, and RRM2 expression in resected pancreas adenocarcinoma: Implications for adjuvant treatment. J ClinOncol2012. 30: (suppl 4; abstr 206.)

Maithel SK, Coban I, Kneuertz PJ, Kooby DA, El-Rayes BF, Kauh JS, Sarmiento J, Staley CA 3rd, VolkanAdsay N. Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection.

Mitchell Cancer Institute. Mobile, AL, USA
How to Cite
RussoS., JainA., & SaifM. (2012). Adjuvant Strategies for Resectable Pancreatic Cancer: Have We Made Progress?. JOP. Journal of the Pancreas, 13(2), 139-142.
Highlights from the “2012 ASCO Gastrointestinal Cancers Symposium”. San Francisco, CA, USA. January 19-21, 2012

Most read articles by the same author(s)